Related Experiment Video

Updated: Mar 20, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada

W Herring1, I Pearson2, M Purser1

  • 1RTI Health Solutions, Research Triangle Park, NC, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K

Related Experiment Videos

Last Updated: Mar 20, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.7K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database.

ESMO real world data and digital oncology·2026

Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access.

Journal of medical economics·2026

The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.

Current medical research and opinion·2019

Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

Current oncology (Toronto, Ont.)·2016

Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada.

Current oncology (Toronto, Ont.)·2014

Development and validation of a cost-utility model for Type 1 diabetes mellitus.

Diabetic medicine : a journal of the British Diabetic Association·2014

Health Utilities and Costs for Multiple Sclerosis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Reconciling Conflicting Evidence on Peri-Immune Checkpoint Inhibitor COVID-19 mRNA Vaccination in Lung Cancer: A Time-Aligned Target Trial Emulation-Informed Landmark Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Assessing the Value of Digital Health Interventions: A Systematic Review of Evaluation Frameworks and Approaches, Key Dimensions and Criteria.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Evaluating the cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care: the UK-ROX trial.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Recommendations on the Implementation of Performance Outcome Assessments in Clinical Trials: A Good Practices Report of an ISPOR Task Force.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Exploring the Expanding Role of Nuclear Receptor LRH-1/NR5A2 in Cell Biology and Immunity.

International journal of cell biology·2026

Cuproptosis-related molecular alterations in a neonatal rat model of hypoxic-ischemic brain damage.

Frontiers in neurology·2026

Off-Target MAP2K7 Inhibition Drives the Antileukemic Activity of the PD-1/PD-L1 inhibitor ACS-69 in Pediatric T-ALL.

Research square·2026

A CRISPR-Cas9 platform for primary human hepatocytes enables arrayed screening and in vivo validation of HBV host factors.

bioRxiv : the preprint server for biology·2026

Myeloid differentiation-associated autophagy drives venetoclax resistance in AML.

Research square·2026

Structure of full-length APOBEC3B bound to EBV BORF2 reveals coordinated neutralization of a cancer-associated mutator.

Research square·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us